https://mindmedicinelaw.com/briefing/spacoda-advances-spatial-transcriptomics-for-brain-research-20261113-58811The Psychedelic Journalen2026-11-14T22:05:17.515234+00:00SpaCoDA Advances Spatial Transcriptomics for Brain Researchspatial transcriptomics, spacoda, cellular niches, neuropsychiatric research, psychedelic science, computational biology, glioblastoma, breast cancer, clinical trials, brain tissue analysishttps://mindmedicinelaw.com/briefing/safety-and-implementation-of-ketamine-psilocybin-and-rtms-for-trd-2026-review-20261113-58838The Psychedelic Journalen2026-11-14T22:05:04.853693+00:00Safety and Implementation of Ketamine, Psilocybin, and rTMS for TRD: 2026 Reviewtreatment-resistant depression, ketamine, psilocybin, esketamine, rTMS, safety monitoring, maintenance strategies, implementation research, psychedelic-assisted therapy, real-world outcomeshttps://mindmedicinelaw.com/briefing/validated-uplc-ms-ms-assay-for-esketamine-metabolites-in-beagle-dogs-20261112-58840The Psychedelic Journalen2026-11-14T22:05:47.288533+00:00Validated UPLC-MS/MS Assay for Esketamine Metabolites in Beagle Dogsesketamine, pharmacokinetics, beagle dog model, UPLC-MS/MS, bioanalytical validation, noresketamine, hydroxynoresketamine, antidepressant research, psychedelic drug developmenthttps://mindmedicinelaw.com/briefing/critique-of-entropic-brain-and-irruption-theories-in-psychedelic-neuroscience-20261112-58792The Psychedelic Journalen2026-11-14T22:05:31.057930+00:00Critique of Entropic Brain and Irruption Theories in Psychedelic Neuroscienceentropic brain hypothesis, irruption theory, neural entropy, psychedelic neuroscience, consciousness research, subjective experience, neuroimaging, clinical trial endpoints, philosophy of mindhttps://mindmedicinelaw.com/briefing/real-world-psilocybin-assessment-protocol-advances-depression-trial-20261112-58558The Psychedelic Journalen2026-11-13T22:07:21.074992+00:00Real-World Psilocybin Assessment Protocol Advances Depression Trialpsilocybin, major depressive disorder, ecological momentary assessment, ambulatory monitoring, clinical trial protocol, adverse effects, real-world evidence, Emory University, FDA, psychedelic therapyhttps://mindmedicinelaw.com/briefing/ketamine-therapy-use-rises-among-u-s-veterans-policy-and-research-gaps-20261112-58471The Psychedelic Journalen2026-11-13T15:06:33.626396+00:00Ketamine Therapy Use Rises Among U.S. Veterans: Policy and Research Gapsketamine therapy, veterans mental health, off-label use, depression treatment, psychedelic policy, FDA regulation, VA healthcare, clinical trials, treatment-resistant depression, psychedelic clinicshttps://mindmedicinelaw.com/briefing/us-federal-funding-for-ibogaine-ptsd-trials-policy-and-research-implications-20261112-58469The Psychedelic Journalen2026-11-13T15:06:17.243241+00:00US Federal Funding for Ibogaine PTSD Trials: Policy and Research Implicationsibogaine, ptsd, federal funding, clinical trials, psychedelic policy, trump administration, veterans affairs, fda, regulatory change, psychedelic researchhttps://mindmedicinelaw.com/briefing/aphantasia-ptsd-intrusions-and-psychedelic-therapy-implications-for-trial-design-20261111-58544The Psychedelic Journalen2026-11-13T22:08:55.125520+00:00Aphantasia, PTSD Intrusions, and Psychedelic Therapy: Implications for Trial Designaphantasia, ptsd intrusions, mental imagery, psychedelic therapy, clinical trial design, trauma research, regulatory policy, neurodiversity, outcome measureshttps://mindmedicinelaw.com/briefing/dmt-and-harmine-modulate-il10-in-trd-patient-microglia-early-mechanistic-evidenc-20261111-58561The Psychedelic Journalen2026-11-13T22:08:39.802152+00:00DMT and Harmine Modulate IL10 in TRD Patient Microglia: Early Mechanistic Evidencedmt, harmine, il10, treatment-resistant depression, microglia, neuroinflammation, biomarkers, psychedelic research, mechanistic studieshttps://mindmedicinelaw.com/briefing/adiponectin-frontothalamic-pathway-and-rapid-antidepressant-effects-implications-20261111-58562The Psychedelic Journalen2026-11-13T22:08:21.465107+00:00Adiponectin-Frontothalamic Pathway and Rapid Antidepressant Effects: Implications for Psychedelic and Exercise-Based Interventionsadiponectin, frontothalamic pathway, acute exercise, rapid antidepressant effects, anterior cingulate cortex, thalamus, psychedelic mechanisms, exercise prescription, endocrine modulation, depression treatmenthttps://mindmedicinelaw.com/briefing/dmt-harmine-retreat-study-reveals-network-specific-brain-effects-20261111-58543The Psychedelic Journalen2026-11-13T22:08:05.150119+00:00DMT/Harmine Retreat Study Reveals Network-Specific Brain Effectsdmt, harmine, psychedelic retreat, brain network control energy, afterglow effects, central executive network, timescale dynamics, connectome modeling, clinical trial, neuroimaginghttps://mindmedicinelaw.com/briefing/clinical-challenges-of-novel-psychoactive-substances-risks-and-policy-gaps-20261111-58559The Psychedelic Journalen2026-11-13T22:07:49.770622+00:00Clinical Challenges of Novel Psychoactive Substances: Risks and Policy Gapsnovel psychoactive substances, next-generation psychedelics, synthetic cannabinoids, designer benzodiazepines, synthetic opioids, toxicology detection, regulatory policy, clinical management, harm reduction, drug surveillancehttps://mindmedicinelaw.com/briefing/ketamine-matches-ect-for-treatment-resistant-depression-clinical-and-policy-impl-20261111-58571The Psychedelic Journalen2026-11-13T22:07:35.884928+00:00Ketamine Matches ECT for Treatment-Resistant Depression: Clinical and Policy Implicationsketamine, treatment-resistant depression, electroconvulsive therapy, clinical guidelines, adverse effects, insurance coverage, psychiatric practice, comparative efficacy, NMDA antagonist, mental health policyhttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-suicidal-ideation-new-meta-analysis-highlights-evide-20261111-58560The Psychedelic Journalen2026-11-13T22:07:06.252341+00:00Ketamine and Esketamine for Suicidal Ideation: New Meta-Analysis Highlights Evidence Gapsketamine, esketamine, suicidal ideation, depression, meta-analysis, randomized controlled trials, safety, efficacy, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/ketamine-and-psychedelics-mechanisms-of-rapid-antidepressant-action-20261111-58572The Psychedelic Journalen2026-11-13T22:06:51.779427+00:00Ketamine and Psychedelics: Mechanisms of Rapid Antidepressant Actionketamine, psychedelics, rapid antidepressant, neuroplasticity, treatment-resistant depression, mechanism of action, clinical trial design, biomarkers, cell-type specificity, policy implicationshttps://mindmedicinelaw.com/briefing/intranasal-nanocarrier-cns-delivery-lessons-for-psychedelic-trials-20261110-58584The Psychedelic Journalen2026-11-14T15:04:17.984929+00:00Intranasal Nanocarrier CNS Delivery: Lessons for Psychedelic Trialsintranasal delivery, nanocarriers, central nervous system, multiple sclerosis, psychedelic research, drug delivery, clinical translation, pharmacokinetics, regulatory sciencehttps://mindmedicinelaw.com/briefing/compass-pathways-seeks-fda-approval-for-psilocybin-therapy-in-us-20261110-58644The Psychedelic Journalen2026-11-13T22:06:33.894710+00:00Compass Pathways Seeks FDA Approval for Psilocybin Therapy in UScompass pathways, psilocybin therapy, fda approval process, treatment-resistant depression, clinical trial phase 3, psychedelic-assisted therapy, regulatory precedent, risk evaluation, market competition, insurance reimbursementhttps://mindmedicinelaw.com/briefing/fda-weighs-psilocybin-approval-for-depression-us-policy-and-clinical-implication-20261110-58470The Psychedelic Journalen2026-11-13T15:05:59.513470+00:00FDA Weighs Psilocybin Approval for Depression: US Policy and Clinical Implicationspsilocybin, fda approval, depression treatment, psychedelic research, clinical trials, controlled substances act, insurance coverage, mental health policy, risk mitigation, us regulatory landscapehttps://mindmedicinelaw.com/briefing/audit-of-llm-mental-health-recommendations-psychedelic-guidance-and-regulatory-g-20261109-58534The Psychedelic Journalen2026-11-14T15:04:31.477052+00:00Audit of LLM Mental Health Recommendations: Psychedelic Guidance and Regulatory Gapslarge language models, mental health interventions, psychedelic therapies, clinical recommendations, ai regulation, audit, digital health, risk assessment, ethics, patient safetyhttps://mindmedicinelaw.com/briefing/ai-in-psychedelic-clinical-trials-llm-applications-and-evidence-gaps-20261109-58024The Psychedelic Journalen2026-11-13T15:07:39.000350+00:00AI in Psychedelic Clinical Trials: LLM Applications and Evidence Gapslarge language models, clinical trial design, psychedelic research, ai validation, trial recruitment, regulatory compliance, data analysis, operational risks, automation bias, governance frameworkshttps://mindmedicinelaw.com/briefing/psychedelics-for-gambling-disorder-clinical-evidence-and-research-gaps-20261109-58061The Psychedelic Journalen2026-11-13T15:07:14.314884+00:00Psychedelics for Gambling Disorder: Clinical Evidence and Research Gapspsychedelics, gambling disorder, clinical trials, neuroplasticity, psilocybin, ketamine, MDMA, regulatory policy, behavioral addiction, treatment researchhttps://mindmedicinelaw.com/briefing/genetic-targets-for-depression-multi-omics-study-guides-future-drug-development-20261109-58063The Psychedelic Journalen2026-11-13T15:07:01.300475+00:00Genetic Targets for Depression: Multi-Omics Study Guides Future Drug Developmentmajor depressive disorder, mendelian randomization, multi-omics, genetic targets, neuroinflammation, immune regulation, psychedelic therapeutics, clinical trial design, drug developmenthttps://mindmedicinelaw.com/briefing/psychedelic-and-medication-use-in-fnd-evidence-and-policy-gaps-20261109-58234The Psychedelic Journalen2026-11-13T15:06:46.012902+00:00Psychedelic and Medication Use in FND: Evidence and Policy Gapsfunctional neurological disorder, FND, psychedelics, ketamine, antidepressants, medication harm, deprescribing, randomized controlled trials, psychotherapy, polypharmacy